By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IntegenX today announced it has raised $40 million in a Series C financing round for the further development of its product pipeline and commercialization of its RapidHIT 200 Human Identification System.

Leading the round was new investor Essex Woodlands, a healthcare growth equity and venture capital firm. Existing investors Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, RONAholdings, Samsung Ventures, and strategic partner In-Q-Tel also participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.